Improved survival and reduced alcohol-associated hepatitis risk with renin-angiotensin-aldosterone system inhibitors in alcohol-associated liver disease.

Key Points

• The study aims to evaluate the impact of RAAS inhibitors on outcomes in patients with alcohol-associated liver disease (ALD).
• Analyzed data from a large cohort of patients with ALD.
• Evaluated the use of ACE inhibitors (ACEI) and angiotensin receptor blockers (ARB).
• Assessed outcomes including mortality, cardiovascular events, liver events, alcohol-associated hepatitis (AH), and sepsis.
• ACEI/ARB use is associated with lower mortality rates.
• Reduced cardiovascular and liver event risks were found in patients using RAAS inhibitors.
• A significant decrease in the occurrence of AH and sepsis was observed.